Eurofins stock: 9M revenue rises as 2026 growth view softens

Eurofins reported improving organic growth through the first nine months of 2026, but lowered its full-year organic-growth expectation. In the company announcement carried by Business Wire on October 21, Eurofins said reported revenue reached 5,614 million euros in the nine months to September, up 3.7% from the comparable period of 2025.

Eurofins stock traded at 87.78 euros on Lang & Schwarz at 11:50 CET on Friday, November 13. The quote is a current trading indication and is not paired here with a verified Xetra closing comparison.

Quarterly momentum strengthens

Organic revenue growth was 3.0% for the first nine months, or 2.9% after the adjustment for public working days. Momentum improved sequentially: organic growth was 2.5% in the first quarter, 3.0% in the second and 3.5% in the third quarter. The comparable figures after the working-day adjustment were 2.6%, 2.9% and 3.2%.

The third-quarter performance included broad-based improvement in BioPharma. Eurofins said BioPharma Product Testing delivered mid-single-digit growth, while Discovery & Genomics returned to positive growth. The company also reported an expected improvement in its contract development and manufacturing organization business, although other ancillary activities remained mixed.

Regional and business-line picture

Rest of the World was the fastest-growing region, with organic growth of 9.3% in the first nine months. North America grew organically by 2.8%, while Europe advanced 1.9%. Reported revenue increased in all three regions, with Europe contributing 2,946 million euros, North America 2,046 million and the Rest of the World 621 million.

By activity, Life generated organic growth of 4.4% and Consumer & Technology Products Testing grew 7.9%. BioPharma rose 0.9%, while Diagnostic Services & Products increased 0.7%. The figures include the effects of acquisitions and disposals, so reported growth and organic growth describe different scopes of the business.

2026 target becomes less demanding

Eurofins said full-year 2026 organic growth is likely to fall below its previous mid-single-digit objective. Management cited slower-than-normal market conditions after nine months and clinical programmes that are not expected to restart during 2026. At the same time, revenue from acquisitions is expected to exceed the previous annualised objective of 250 million euros, based on transactions already completed.

The company maintained its profitability and cash-flow objectives for 2026 and 2027. Adjusted EBITDA margin is expected to improve in 2026 from the 2025 level of 22.5%, while the 2027 objective remains 24%. Eurofins also expects free cash flow to the firm to grow and cash conversion to remain strong.

Chief Executive Gilles Martin linked the longer-term plan to the group's hub-and-spoke laboratory network, start-up investments, digitalisation projects and productivity gains. For 2027, Eurofins expects to return to mid-single-digit organic growth. The company also said it had completed 22 acquisitions with 2025 revenue above 210 million euros during the first nine months, excluding the North American Life Sciences Testing Services acquisition of Element.

Eurofins Scientific at a glance

• Company: Eurofins Scientific SE
• ISIN: FR0014000MR3
• Trading indication: 87.78 euros on Lang & Schwarz, Friday, November 13, 2026, 11:50 CET
• 9M 2026 revenue: 5,614 million euros
• 9M 2026 reported growth: 3.7%
• 9M 2026 organic growth: 3.0%
• 2027 adjusted EBITDA margin objective: 24%

European laboratory and testing shares remain part of the wider market backdrop represented by the CAC 40.

Further updates and analysis are available on More news and analyses on Eurofins stock.